Literature DB >> 33500361

A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection.

Sean C Taylor1, Beth Hurst2, Carmen L Charlton3,4,5, Ashley Bailey3, Jamil N Kanji3,6, Mary K McCarthy7, Thomas E Morrison7, Leah Huey8,9, Kyle Annen10,11, Melkon G DomBourian10,11, Vijaya Knight8,9.   

Abstract

Many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology tests have proven to be less accurate than expected and do not assess antibody function as neutralizing, correlating with protection from reinfection. A new assay technology measuring the interaction of the purified SARS-CoV-2 spike protein receptor binding domain (RBD) with the extracellular domain of the human angiotensin-converting enzyme 2 (hACE2) receptor detects these important antibodies. The cPass surrogate virus neutralization test (sVNT), compared directly with eight SARS-CoV-2 IgG serology and two live-cell neutralization tests, gives similar or improved accuracy for qualitative delineation between positive and negative individuals in a fast, scalable, and high-throughput assay. The combined data support the cPass sVNT as a tool for highly accurate SARS-CoV-2 immunity surveillance of infected/recovered and/or vaccinated individuals as well as drug and convalescent-phase donor screening. The data also preview a novel application for the cPass sVNT in calibrating the stringency of live-cell neutralization tests and its use in longitudinal testing of recovered and/or vaccinated patients.
Copyright © 2021 Taylor et al.

Entities:  

Keywords:  ELISA; SARS-CoV-2; neutralizing antibodies; serology; vaccines

Year:  2021        PMID： 33500361     DOI： 10.1128/JCM.02438-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  46 in total

Review 1.  Practical guidance for clinical laboratories for SARS-CoV-2 serology testing.

Authors:  Carmen Charlton; Jamil Kanji; Vanessa Tran; Julianne Kus; Jonathan Gubbay; Carla Osiowy; Jason Robinson; Inna Sekirov; Michael Drebot; Todd Hatchette; Derek Stein; Nadia El-Gabalawy; Amanda Lang; Lei Jiao; Paul Levett; Heidi Wood; Christian Therrien; L Robbin Lindsay; Muhammad Morshed; Jessica Forbes; Antonia Dibernardo
Journal:  Can Commun Dis Rep       Date:  2021-05-07

2.  Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay.

Authors:  Z S Mousa; A S Abdulamir
Journal:  Arch Razi Inst       Date:  2022-02-28

3.  Comparison of commercial SARS-CoV-2 surrogate neutralization assays with a full virus endpoint dilution neutralization test in two different cohorts.

Authors:  Ortwin Adams; Marcel Andrée; Derik Hermsen; Nadine Lübke; Jörg Timm; Heiner Schaal; Lisa Müller
Journal:  J Virol Methods       Date:  2022-06-17       Impact factor: 2.623

4.  Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.

Authors:  Flavio Signorelli; Gustavo Guimarães Moreira Balbi; Nadia E Aikawa; Clovis A Silva; Léonard de Vinci Kanda Kupa; Ana C Medeiros-Ribeiro; Emily Fn Yuki; Sandra G Pasoto; Carla Gs Saad; Eduardo F Borba; Luciana Parente Costa Seguro; Tatiana Pedrosa; Vitor Antonio de Angeli Oliveira; Ana Luisa Cerqueira de Sant'Ana Costa; Carolina T Ribeiro; Roseli Eliana Beseggio Santos; Danieli Castro Oliveira Andrade; Eloisa Bonfá
Journal:  Lupus       Date:  2022-05-20       Impact factor: 2.858

5.  Strong response after 4th dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine.

Authors:  Nadia E Aikawa; Leonard V K Kupa; Clovis A Silva; Carla G S Saad; Sandra G Pasoto; Emily F N Yuki; Solange R G Fusco; Samuel K Shinjo; Danieli C O Andrade; Percival D Sampaio-Barros; Rosa M R Pereira; Anna C S Chasin; Andrea Y Shimabuco; Ana P Luppino-Assad; Elaine P Leon; Marta H Lopes; Leila Antonangelo; Ana C Medeiros-Ribeiro; Eloisa Bonfa
Journal:  Rheumatology (Oxford)       Date:  2022-05-26       Impact factor: 7.046

6.  Harmonization of Multiple SARS-CoV-2 Reference Materials Using the WHO IS (NIBSC 20/136): Results and Implications.

Authors:  William Jonathan Windsor; Yannik Roell; Heidi Tucker; Chi-An Cheng; Sara Suliman; Laura J Peek; Gary A Pestano; William T Lee; Heinz Zeichhardt; Molly M Lamb; Martin Kammel; Hui Wang; Ross Kedl; Cody Rester; Thomas E Morrison; Bennet J Davenport; Kyle Carson; Jennifer Yates; Kelly Howard; Karen Kulas; David R Walt; Aner Dafni; Daniel Taylor; May Chu
Journal:  Front Microbiol       Date:  2022-05-30       Impact factor: 6.064

7.  SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus.

Authors:  Giulia Matusali; Francesca Colavita; Daniele Lapa; Silvia Meschi; Licia Bordi; Pierluca Piselli; Roberta Gagliardini; Angela Corpolongo; Emanuele Nicastri; Andrea Antinori; Giuseppe Ippolito; Maria Rosaria Capobianchi; Concetta Castilletti
Journal:  Viruses       Date:  2021-04-10       Impact factor: 5.048

8.  Specificity of SARS-CoV-2 Antibody Detection Assays against S and N Proteins among Pre-COVID-19 Sera from Patients with Protozoan and Helminth Parasitic Infections.

Authors:  Cedric P Yansouni; Momar Ndao; Jesse Papenburg; Matthew P Cheng; Rachel Corsini; Chelsea Caya; Fabio Vasquez Camargo; Luke B Harrison; Gerasimos Zaharatos; Philippe Büscher; Babacar Faye; Magatte Ndiaye; Greg Matlashewski
Journal:  J Clin Microbiol       Date:  2021-10-20       Impact factor: 5.948

9.  Systemic Adverse Events and Use of Antipyretics Predict the Neutralizing Antibody Positivity Early after the First Dose of ChAdOx1 Coronavirus Disease Vaccine.

Authors:  Ji Young Park; Seong-Ho Choi; Jin-Won Chung; Min-Hyung Hwang; Min-Chul Kim
Journal:  J Clin Med       Date:  2021-06-27       Impact factor: 4.241

10.  Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies.

Authors:  Niko Kohmer; Cornelia Rühl; Sandra Ciesek; Holger F Rabenau
Journal:  J Clin Med       Date:  2021-05-14       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.